Daiichi Sankyo US
Highly Engaged Employees
Manufacturing · New Jersey, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
211 Mount Airy Rd, Basking Ridge, New Je...Phone Number
(908) 992-6400Website
www.daiichisankyo.usRevenue
$607.6 MillionIndustry
About Daiichi Sankyo US
Daiichi Sankyo US Org Chart
Is Daiichi Sankyo US your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Daiichi Sankyo US, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Daiichi Sankyo US has recently received funding, and reach out quickly before it becomes old news!
Check out if Daiichi Sankyo US is spiking on competitors!
Click to see if Daiichi Sankyo US had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Daiichi Sankyo US launches new products
Earning: See what the market has to say on Daiichi Sankyo US recently announced quarterly report
Funding: Get notified immidiatlly once Daiichi Sankyo US has new funding data
Congratulate Masked Content for being promoted to Masked Content at Daiichi Sankyo US
Recommended Actions
Find VP level buyers at Daiichi Sankyo US
Find 3 more new buyers
Compare Similar Companies to Daiichi Sankyo US
Compare insights from companies similar to Daiichi Sankyo US, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Daiichi Sankyo US is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Daiichi Sankyo US is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Daiichi Sankyo US.
Daiichi Sankyo US Tech Stack
A closer look at the technologies used by Daiichi Sankyo US
Most Recent Scoops
Daiichi Sankyo US News & Media
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumors in heavily pretreated patients. ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Daiichi Sankyo US
As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability.... Read More